How High Could IBIT Go?
Recently, a surprising number of billionaire hedge fund managers have…
Buy
60
INVA Quote, Financials, Valuation and Earnings
Last price:
$18.12
Seasonality move
:
3.47%
Day range:
$17.84 - $18.34
52-week range:
$14.33 - $21.28
Dividend yield:
0%
P/E ratio:
95.68x
P/S ratio:
4.03x
P/B ratio:
1.65x
Volume:
829.7K
Avg. volume:
978.4K
1-year change:
19.29%
Market cap:
$1.1B
Revenue:
$358.7M
EPS (TTM):
$0.19
Analysts' Opinion
-
Consensus RatingInnoviva has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.00, Innoviva has an estimated upside of 4.51% from its current price of $18.18.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.00 representing 100% downside risk from its current price of $18.18.
Fair Value
-
According to the consensus of 1 analyst, Innoviva has 4.51% upside to fair value with a price target of $19.00 per share.
INVA vs. S&P 500
-
Over the past 5 trading days, Innoviva has overperformed the S&P 500 by 6.9% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Innoviva does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Innoviva has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Innoviva reported revenues of $91.8M.
Earnings Growth
-
Innoviva earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Innoviva reported earnings per share of $0.26.
Enterprise value:
1.2B
EV / Invested capital:
--
Price / LTM sales:
4.03x
EV / EBIT:
19.72x
EV / Revenue:
3.28x
PEG ratio (5yr expected):
0.46x
EV / Free cash flow:
6.37x
Price / Operating cash flow:
7.83x
Enterprise value / EBITDA:
13.75x
Gross Profit (TTM):
$322.1M
Return On Assets:
1.87%
Net Income Margin (TTM):
6.52%
Return On Equity:
3.44%
Return On Invested Capital:
2.07%
Operating Margin:
46.99%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $331.3M | $310.5M | $358.7M | $85.8M | $91.8M | |
| Gross Profit | $317.5M | $267.8M | $322.1M | $72.7M | $84.6M | |
| Operating Income | $207M | $113.9M | $166.9M | $37.5M | $43.1M | |
| EBITDA | $308.3M | $235M | $85.5M | $73.7M | $36M | |
| Diluted EPS | $2.03 | $2.18 | $0.19 | $0.76 | $0.26 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $342.1M | $313.7M | $443.5M | $344.2M | $554.3M | |
| Total Assets | $999.6M | $926.4M | $1.2B | $1.2B | $1.3B | |
| Current Liabilities | $6.1M | $5.8M | $135M | $38.1M | $236.1M | |
| Total Liabilities | $391.7M | $400.5M | $665.7M | $568.6M | $609.9M | |
| Total Equity | $607.8M | $525.9M | $565.8M | $675M | $691.2M | |
| Total Debt | $385.5M | $394.7M | $540.4M | $446.2M | $448.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $201.7M | $141.1M | $188.7M | $33.3M | $59.2M | |
| Cash From Investing | -$56.6M | -$66.8M | -$63.8M | -$5.2M | -$15.5M | |
| Cash From Financing | -$55.6M | -$171.8M | -$13.5M | -$14.6M | $573K | |
| Free Cash Flow | $201.7M | $140.7M | $184.4M | $33.1M | $55.2M | |
INVA
Sector
Market Cap
$1.1B
$36.4M
Price % of 52-Week High
85.43%
44.07%
Dividend Yield
0%
0%
Shareholder Yield
1.19%
-1.03%
1-Year Price Total Return
19.29%
-41.85%
Beta (5-Year)
0.564
0.775
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$17.50
200-day SMA
Sell
Level
$18.34
Bollinger Bands (100)
Sell
Level
17.55 - 19.15
Chaikin Money Flow
Buy
Level
15.9M
20-day SMA
Buy
Level
$17.54
Relative Strength Index (RSI14)
Buy
Level
64.42
ADX Line
Buy
Level
11.95
Williams %R
Sell
Level
-11.985
50-day SMA
Buy
Level
$18.00
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
40.5M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.788)
Buy
CA Score
(Annual)
Level (0.0255)
Buy
Beneish M-Score
(Annual)
Level (-2.7508)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (3.2987)
Buy
Piotroski F Score
(Annual)
Level (7)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.
Stock Forecast FAQ
In the current month, INVA has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The INVA average analyst price target in the past 3 months is $19.00.
-
Where Will Innoviva Stock Be In 1 Year?
According to analysts, the consensus estimate is that Innoviva share price will rise to $19.00 per share over the next 12 months.
-
What Do Analysts Say About Innoviva?
Analysts are divided on their view about Innoviva share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Innoviva is a Sell and believe this share price will drop from its current level to $19.00.
-
What Is Innoviva's Price Target?
The price target for Innoviva over the next 1-year time period is forecast to be $19.00 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is INVA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Innoviva is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of INVA?
You can purchase shares of Innoviva via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Innoviva shares.
-
What Is The Innoviva Share Price Today?
Innoviva was last trading at $18.12 per share. This represents the most recent stock quote for Innoviva. Yesterday, Innoviva closed at $18.18 per share.
-
How To Buy Innoviva Stock Online?
In order to purchase Innoviva stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Raymond James Stock a Buy, Sell or Hold?
Raymond James Financial (NYSE:RJF) is one of America’s large financial…
Is JHX Stock a Buy Sell or Hold?
James Hardie Industries (NYSE:JHX) is a manufacturer of outside building…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
41
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
AJINY alert for Mar 31
Ajinomoto [AJINY] is down 2.15% over the past day.
Sell
40
RGC alert for Mar 31
Regencell Bioscience Holdings [RGC] is up 26.1% over the past day.
Buy
69
AGX alert for Mar 31
Argan [AGX] is down 4.98% over the past day.
